NDAINTRAVENOUSSOLUTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
CYCLOPHOSPHAMIDE (cyclophosphamide) by Dr. Reddy's Laboratories is alkylating activity [moa]. Approved for iv of the ann arbor staging system), hodgkin's disease, lymphocytic lymphoma (nodular and 12 more indications. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cyclophosphamide is an intravenous alkylating chemotherapy agent used to treat hematologic malignancies including Hodgkin's disease, lymphomas, multiple myeloma, and various leukemias. It works by cross-linking DNA strands, preventing cell replication and triggering apoptosis in rapidly dividing cancer cells. The drug is often used sequentially with other antineoplastic agents to enhance therapeutic efficacy.
Peak9.8 years to LOE
Product is at peak commercial maturity with established market presence; Dr. Reddy's likely maintains focused commercial infrastructure with stable sales force and marketing investment.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications (15)
Worked on CYCLOPHOSPHAMIDE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.